Bianca Maria Veneziani

ORCID: 0000-0002-1678-4183
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Cells and Metastasis
  • Sphingolipid Metabolism and Signaling
  • Cytokine Signaling Pathways and Interactions
  • PI3K/AKT/mTOR signaling in cancer
  • Epigenetics and DNA Methylation
  • HER2/EGFR in Cancer Research
  • ATP Synthase and ATPases Research
  • Growth Hormone and Insulin-like Growth Factors
  • Cancer-related gene regulation
  • Cancer Genomics and Diagnostics
  • Microtubule and mitosis dynamics
  • Cancer Treatment and Pharmacology
  • Hedgehog Signaling Pathway Studies
  • Lung Cancer Treatments and Mutations
  • RNA modifications and cancer
  • Cancer, Hypoxia, and Metabolism
  • Caveolin-1 and cellular processes
  • Nanoplatforms for cancer theranostics
  • Breast Cancer Treatment Studies
  • Angiogenesis and VEGF in Cancer
  • Thyroid Disorders and Treatments
  • MicroRNA in disease regulation
  • Extracellular vesicles in disease
  • Cancer Risks and Factors
  • Cancer, Lipids, and Metabolism

University of Naples Federico II
2011-2024

Federico II University Hospital
2015-2023

National Research Council
2011-2012

Ceinge Biotecnologie Avanzate (Italy)
1994-2012

Institute for Experimental Endocrinology and Oncology
1997-2011

Opera Software (Norway)
1999

University of Reggio Calabria
1990-1993

Harvard University
1989

Beth Israel Deaconess Medical Center
1988

Istituto Nazionale di Fisica Nucleare, Sezione di Napoli
1986

Several evidences suggest a marked angiogenic dependency in triple-negative breast cancer (TNBC) tumorigenesis and potential sensitivity to anti-angiogenic agents. Herein, the putative role of Hedgehog (Hh) pathway regulating TNBC-dependent angiogenesis was investigated.Expression regulation Hh transcription factor glioma-associated oncogene homolog1 protein (GLI1) were studied on endothelial compartment TNBC-initiated angiogenesis. To evaluate translational relevance our findings,...

10.1038/bjc.2017.116 article EN cc-by-nc-sa British Journal of Cancer 2017-04-25

In previous studies we have demonstrated that bovine TSH (bTSH) and insulin-like growth factor I (IGF-I) independently stimulate both the incorporation of [3H]thymidine into DNA replication in quiescent FRTL5 cells. case TSH, evidence was presented these responses are cAMP mediated. addition, thymidine greatly amplified when particular concentrations two agents added together, but this effect diminishes as concentration either bTSH or IGF-I is increased. The present experiments were...

10.1210/endo-122-1-127 article EN Endocrinology 1988-01-01

Although the anti-EGF receptor (EGFR) monoclonal antibody cetuximab is an effective strategy in colorectal cancer therapy, its clinical use limited by intrinsic or acquired resistance. Alterations "sphingolipid rheostat"-the balance between proapoptotic molecule ceramide and mitogenic factor sphingosine-1-phosphate (S1P)-due to sphingosine kinase 1 (SphK1) overactivation have been involved resistance anticancer-targeted agents. Moreover, cross-talks SphK1 EGFR-dependent signaling pathways...

10.1158/1078-0432.ccr-12-1050 article EN Clinical Cancer Research 2012-11-20

Cetuximab is the only targeted agent approved for treatment of head and neck squamous cell carcinomas (HNSCC), but low response rates disease progression are frequently reported. As phosphoinositide 3-kinase (PI3K) mammalian target rapamycin (mTOR) pathways have an important role in pathogenesis HNSCC, we investigated their involvement cetuximab resistance. Different human cancer lines sensitive or resistant to were tested dual PI3K/mTOR inhibitor PF-05212384 (PKI-587), alone combination,...

10.1038/bjc.2014.241 article EN cc-by-nc-sa British Journal of Cancer 2014-05-13

The urokinase-type plasminogen activator receptor (uPAR) is a GPI-anchored cell membrane that focuses urokinase (uPA) proteolytic activity on the surface. Its expression increased in many human cancers, including non-small lung cancer (NSCLC) and colorectal (CRC), correlates with poor prognosis early invasion metastasis. uPAR able to control, through cross-talk tyrosine kinase receptors, shift between tumor dormancy proliferation, usually precedes metastasis formation. Therefore, we...

10.1038/s41598-017-10062-1 article EN cc-by Scientific Reports 2017-08-18

We investigated the effects of photodynamic therapy (PDT) combined with low-dose chemotherapy on breast cancer cells. Photodynamic treatment was administered by irradiating indocyanine green-preloaded MCF-7 cells an IR diode laser source at 805 nm; cisplatin used for chemotherapy.The dose-response phenomena associated two treatments individually and together were evaluated following tests: trypan blue dye exclusion, 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide (MTT) assay,...

10.1158/1535-7163.537.3.5 article EN Molecular Cancer Therapeutics 2004-05-01

Src tyrosine kinase overactivation has been correlated with a poor response to human epidermal growth factor receptor 2 (HER2) inhibitors in breast cancer. To identify the mechanism by which overexpression sustains this resistance, we tested panel of cancer cell lines either sensitive or resistant lapatinib.To determine role lapatinib evaluated effects inhibition/silencing vitro on survival, migration, and invasion lapatinib-resistant cells. In vivo experiments were performed JIMT-1 cells...

10.1186/bcr3650 article EN cc-by Breast Cancer Research 2014-05-05

Multiple lines of evidence support that the Hedgehog (Hh) signalling has a role in maintenance and progression different human cancers. Therefore, inhibition Hh pathway represents valid anticancer therapeutic approach for renal cell carcinoma (RCC) patients. NVP-LDE225 is Smoothened (Smo) antagonist induces dose-related Smo-dependent tumour growth. We assayed effects alone or combination with everolimus sunitinib on growth invasion RCC models both vitro vivo. To this aim, we used panel...

10.1038/bjc.2014.421 article EN cc-by-nc-sa British Journal of Cancer 2014-08-05

Abstract Introduction Real-time monitoring of biologic changes in tumors may be possible by investigating the transitional cells such as circulating tumor (CTCs) and disseminated bone marrow (BM-DTCs). However, small numbers CTCs limited access to aspirates cancer patients pose major hurdles. The goal this study was determine whether breast (BC) patient-derived xenograft (PDX) mice could provide a constant renewable source BM-DTCs, thereby representing unique system for metastatic processes....

10.1186/s13058-014-0508-5 article EN cc-by Breast Cancer Research 2015-01-08

Abstract We compared the effects of monotherapy (photodynamic therapy or chemotherapy) versus combination plus a specific drug) on non–small cell lung cancer line H1299. Our aim was to evaluate whether additive/synergistic treatment were such that cytostatic dose could be reduced without affecting efficacy. Photodynamic done by irradiating Photofrin-preloaded H1299 p53/p16-null cells with halogen lamp equipped bandpass filter. The cytotoxic drugs used cis-diammine-dichloroplatinum [II] (CDDP...

10.1158/1535-7163.mct-05-0425 article EN Molecular Cancer Therapeutics 2006-03-01

Weight gain and metabolic changes have been related to survival of early breast cancer patients (EBC). ''However, factors influencing metabolism post-diagnosis are not fully understood. We measured anthropometric [body mass index (BMI), body weight, waist hip circumferences, waist-to-hip ratio] (levels insulin, glucose, H1Ac, total, HDL, LDL cholesterol, triglycerides, the homeostasis model assessment score [HOMA]) parameters in 433 pre- post-menopausal women with EBC at diagnosis 3, 6, 9,...

10.1007/s10549-015-3586-x article EN cc-by-nc Breast Cancer Research and Treatment 2015-09-30

Abstract Purpose: The epidermal growth factor receptor (EGFR) autocrine pathway plays an important role in cancer cell growth. Vascular endothelial A (VEGF‐A) is a key regulator of tumor‐induced proliferation and vascular permeability. ZD6474 orally available, small molecule inhibitor VEGF receptor‐2 (VEGFR‐2), EGFR RET tyrosine kinase activity. We investigated the activity combination with cetuximab, anti‐EGFR blocking monoclonal antibody, to determine anti‐tumor blockade through combined...

10.1002/jcp.20666 article EN Journal of Cellular Physiology 2006-05-10

Abstract To determine whether cell cultures maintain the cellular heterogeneity of primary tissues and may therefore be used for in vitro modeling breast cancer subtypes, we evaluated expression a surface marker panel derived from various subtypes human carcinoma. We four‐color flow cytometry strategy to immunophenotype seven four reference lines. analyzed 28 markers selected based on their potential distinguish epithelial or mesenchymal lineage, identify stem populations, mediate adhesion...

10.1002/cyto.a.22095 article EN Cytometry Part A 2012-07-12

// Luigi Formisano 1 , Valentina D'Amato Alberto Servetto Simona Brillante Lucia Raimondo Concetta Di Mauro Roberta Marciano Clara Orsini Sandro Cosconati 2 Antonio Randazzo 3 Sarah J. Parsons 4 Nunzia Montuori 5 Bianca Maria Veneziani 6 Sabino De Placido Rosa 1, * Roberto Bianco Department of Clinical Medicine and Surgery, University Naples "Federico II", Naples, Italy DiSTABiF, Second Caserta, Pharmacy, Microbiology, Immunology & Cancer Biology, Center, Virginia Health System,...

10.18632/oncotarget.4636 article EN Oncotarget 2015-08-03

Charcot-Marie-Tooth type 2B (CMT2B) disease is a dominant axonal peripheral neuropathy caused by 5 mutations in the RAB7A gene, ubiquitously expressed GTPase controlling late endocytic trafficking. In neurons, also controls neuronal-specific processes such as NTF (neurotrophin) trafficking and signaling, neurite outgrowth neuronal migration. Given involvement of macroautophagy/autophagy several neurodegenerative diseases considering that fundamental for autophagosome maturation, we...

10.1080/15548627.2017.1388475 article EN Autophagy 2017-11-13

Background HER2 is amplified or overexpressed in around 20% of breast cancers (BC). HER2-targeted therapies have significantly improved the prognosis patients with HER2+ BC, however, de novo and acquired resistance to anti-HER2 treatment common. Activating mutations PIK3CA gene are reported ∼30% BC associated a poor prognosis. Here, we investigated vitro vivo antitumor efficacy alpha-specific PI3K inhibitor alpelisib alone combination therapy using panel cell lines. We also generated models...

10.3389/fonc.2023.1108242 article EN cc-by Frontiers in Oncology 2023-07-04

In studies of regulation the growth and differentiated function thyroid follicular cell, we have employed FRTL5 cell line to evaluate both effects agents that activate protein kinase-C (PKC) their interaction with other influence and/or cell. The PKC activator tetradecanoyl-phorbol acetate (TPA) alone induced a time- concentration-dependent stimulation incorporation [3H]thymidine into DNA quiescent cells, an effect anteceded by increase in levels mRNAs proto-oncogene c-myc associated...

10.1210/endo-123-3-1544 article EN Endocrinology 1988-09-01
Coming Soon ...